Literature DB >> 26619172

Rationale for the 2010 Revised Susceptibility Breakpoints for Cephalosporins, Aztreonam, and Carbapenems for Enterobacteriaceae.

Michael N Dudley1.   

Abstract

Entities:  

Year:  2012        PMID： 26619172     DOI： 10.1093/jpids/pis046

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN： 2048-7193            Impact factor:   3.164


× No keyword cloud information.
  6 in total

Review 1.  Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae.

Authors:  Elizabeth A Neuner; Jason C Gallagher
Journal:  Virulence       Date:  2016-08-09       Impact factor: 5.882

Review 2.  Impact of 21st Century Cures Act on Breakpoints and Commercial Antimicrobial Susceptibility Test Systems: Progress and Pitfalls.

Authors:  Romney M Humphries; Mary Jane Ferraro; Janet A Hindler
Journal:  J Clin Microbiol       Date:  2018-04-25       Impact factor: 5.948

3.  Antibiotic Breakpoints: How Redefining Susceptibility Preserves Efficacy and Improves Patient Care.

Authors:  Mark Redell; Glenn Tillotson
Journal:  P T       Date:  2019-09

Review 4.  Screening for carbapenem-resistant Enterobacteriaceae: Who, When, and How?

Authors:  Sandra S Richter; Dror Marchaim
Journal:  Virulence       Date:  2016-11-04       Impact factor: 5.882

Review 5.  The Practical Problem With Carbapenem Testing and Reporting Accurate Bacterial Susceptibilities.

Authors:  Mark Redell; Glenn S Tillotson
Journal:  Front Pharmacol       Date:  2022-04-25       Impact factor: 5.988

6.  Raising the Bar: Improving Antimicrobial Resistance Detection by Clinical Laboratories by Ensuring Use of Current Breakpoints.

Authors:  Patricia J Simner; Carol A Rauch; Isabella W Martin; Kaede V Sullivan; Daniel Rhoads; Robin Rolf; Rosemary She; Rhona J Souers; Christina Wojewoda; Romney M Humphries
Journal:  Open Forum Infect Dis       Date:  2022-02-07       Impact factor: 3.835
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.